This phase III trial is evaluating a chemotherapy-steroid combination as maintenance therapy for transplant-eligible multiple myeloma (MM) patients who are undergoing single autologous stem cell transplantation (ASCT) as part of front-line therapy.
This trial is treating patients with multiple myeloma.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3 trial of thalidomide-dexamethasone consolidation versus thalidomide-dexamethasone-Ixazomib consolidation for transplant eligible multiple myeloma patients undergoing a single ASCT as part of front-line therapy
Australasian Leukaemia and Lymphoma Group (ALLG)
Patients enrolled in this trial will be randomised 1:1 into the control or experimental arm. Patients in the control arm will receive thalidomide and dexamethasone. Patients in the experimental arm will receive the control treatment plus ixazomib.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More